Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: infliximab

Real-Life Rheumatology: Clinical Pearls for Psoriatic Arthritis

Jason Liebowitz, MD, FACR  |  March 23, 2022

At the 17th Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases meeting, Ana-Maria Orbai, MD, MHS, discussed lessons learned from the cases of several patients with psoriatic arthritis.

Filed under:ConditionsMeeting ReportsPsoriatic Arthritis Tagged with:Advances in the Diagnosis and Treatment of the Rheumatic Diseases meetingClinical RheumatologyPractice PearlsPsoriatic Arthritis

Case Report: Atypical Presentation of Idiopathic Retroperitoneal Fibrosis

Roshniben Patel, MD, Simon Go, MD, Akhila Mohan, MD, & Maria Pardi, MD  |  March 14, 2022

Retroperitoneal fibrosis (RPF) is a rare condition characterized by aberrant fibroinflammatory tissue developing in the retroperitoneum. This disorder was initially called Ormond’s disease. RPF may be idiopathic or secondary to other conditions. Idiopathic RPF is a part of the disease spectrum of chronic periaortitis due to its typical periaortoiliac localization. Idiopathic retroperitoneal fibrosis is a…

Filed under:Conditions Tagged with:case reportfibrosiskidneyOrmond's Diseaseretroperitoneal fibrosis (RPF)

The Ins & Outs of Patient Assistance Programs

Samantha C. Shapiro, MD  |  March 3, 2022

Although effective against rheumatic disease, biologic therapies come with hefty price tags. Patient assistance programs can be a useful resource to help under- and uninsured patients get the drugs they need.

Filed under:Biologics/DMARDsDrug UpdatesPractice Support Tagged with:biologic therapiesdrug costsfederally qualified health centerpatient assistance programs (PAP)patient careuninsured Americans

Drug Transference in Pregnancy: RheumMadness 2022 TNFi in Cord Blood Scouting Report

University of Chicago Medicine: Lauren He, MD; & Cuoghi Edens, MD  |  March 2, 2022

A study was able to quantify the transference of tumor necrosis factor (TNF) inhibitors from mother to fetus during pregnancy. Overall, the researchers found low levels of transfer for the treatments studied.

Filed under:ConditionsDrug UpdatesResearch Rheum Tagged with:cord blooddrug transferencepregnancyRheumMadnessTNFitumor necrosis factor inhibitor (TNFi)

Andrew Brookes / Image Source on Offset

Clinical Insights into Axial Spondyloarthritis: Rheumatology Drugs at a Glance, Part 5

Mary Choy, PharmD, BCGP, FASHP  |  February 10, 2022

Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options; others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…

Filed under:Axial SpondyloarthritisBiologics/DMARDsConditionsDrug Updates Tagged with:Ankylosing SpondylitisAS Resource Center

MIA Studio / shutterstock.com

Kawasaki Guideline Urges Treatment Intensification for Some Patients

Ruth Jessen Hickman, MD  |  December 16, 2021

A soon-to-be published guideline from the ACR and the Vasculitis Foundation on Kawasaki disease underscores the importance of early diagnosis and intensified treatment for people with this serious condition.1 Intravenous immunoglobulin (IVIG) remains the treatment mainstay, and prompt, aggressive treatment may be able to reduce the risk of serious complications in some patients. The guideline…

Filed under:Clinical Criteria/GuidelinesConditionsVasculitis Tagged with:Kawasaki diseaseVasculitis

Management of Adults with JIA: Uveitis, MAS & More

Mary Beth Nierengarten  |  December 2, 2021

Mara L. Becker, MD, MSCE, discusses how important it is to effectively treat juvenile idiopathic arthritis at an early stage to improve long-term outcomes in adulthood.

Filed under:ACR ConvergenceConditionsMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2021ACR Convergence 2021 – RAJIAjuvenile idiopathic arthritis (JIA)macrophage activation syndrometumor necrosis factor (TNF) inhibitorsUveitis

How to Find Space for Scholarship in Private Practice

Jason Liebowitz, MD, FACR  |  November 14, 2021

A key question many graduating rheumatology fellows face each year is: Are you interested in pursuing a career in academic medicine or in private practice? Although the two tracks are not mutually exclusive, it is true that juggling the demands of scholarly work, medical education and a busy clinical workload is by no means easy….

Filed under:Career DevelopmentProfessional TopicsResearch Rheum Tagged with:AcademiaResearchScholarship

TNF Inhibitors & Pregnancy: How Well Does the Treatment Guidance Work?

Michele B. Kaufman, PharmD, BCGP  |  October 21, 2021

Ghalandari et al. sought to validate the guidance outlined by EULAR for the use of anti-rheumatic drugs during pregnancy, finding that following its guidance for tumor necrosis factor inhibitors led to no or low concentrations of these agents in cord blood.

Filed under:Drug UpdatesEULAR/OtherMeeting Reports Tagged with:EULARpregnancypregnant womenTNF inhibitorsTNFiWomen

A Dematologist’s Perspective on Choosing an Anti-Psoriatic Drug

Samantha C. Shapiro, MD  |  October 15, 2021

We are fortunate to have clinical practice guidelines for the management of psoriasis and psoriatic arthritis (PsA) from multiple organizations to help navigate today’s rapidly evolving therapeutic landscape. We are further fortunate to have multiple specialists to manage these conditions: rheumatologists and dermatologists. However, multiple guidelines, multiple drugs and multiple specialists can create a paradox…

Filed under:Biologics/DMARDsConditionsPsoriatic Arthritis Tagged with:Psoriatic Arthritis

  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 41
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences